New insider activity at Krystal Biotech ( (KRYS) ) has taken place on February 26, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Krystal Biotech director Daniel Janney has recently executed a major stock sale, offloading 37,895 shares of the company’s stock in a transaction valued at $10,113,058. This sizable move by an insider highlights significant trading activity at the executive level and may draw attention from investors monitoring leadership’s stake in Krystal Biotech.
Recent Updates on KRYS stock
Krystal Biotech shares reacted to a cluster of bullish analyst model updates following its Q4 earnings. Guggenheim, Citi, Chardan and Jefferies all raised targets after the company reported strong Vyjuvek revenue growth, durable high margins, and a nearly $1B cash position, while demonstrating profitable expansion despite cost inflation and ex‑U.S. launch friction.
Analysts also cited higher projected Vyjuvek sales, especially in the U.S. with rising prescriber adoption and early international traction, as key drivers. Further support came from advancing late‑stage and registrational gene‑therapy programs, favorable regulatory designations, and upcoming pivotal data that collectively enhance the long‑term growth outlook and justify richer valuation assumptions.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Score is driven primarily by strong financial performance (profitability and cash flow improvement with minimal leverage) and a constructive earnings outlook (high-margin guidance, strong cash runway, and positive pipeline/regulatory progress). Offsetting factors are premium valuation (P/E ~41.5) and some near-term execution/visibility risks (higher planned spend and European pricing/revenue timing), while technicals remain positive but not strongly overextended.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
YTD Price Performance: 10.53%
Average Trading Volume: 310,040
Technical Sentiment Signal: Buy
Current Market Cap: $7.8B